Clinical Development Pipeline
CLARIFY and AMPLIFY are being conducted in the US and in Australia. SECuRE is being conducted in the US. SARTATE Phase III is planned to be conducted in the US. Pipeline assets as of 05 Aug 2026. Data on file.
Products in Development
Clarity’s theranostic programs aim to increase the probability of treatment success by selecting patients that demonstrate uptake of the diagnostic agents to visualise their cancer prior to therapy.
For indications such as prostate cancer and neuroendocrine tumours (NETs), the diagnostic products based on copper-64 (Cu-64) are also in development as stand-alone products to diagnose and manage disease in a broader spectrum of patients.
Clarity’s clinical pipeline is focused on theranostic product development for the following indications:
- Prostate cancer therapy with 64/67Cu-SAR-bisPSMA
Diagnostic studies are also underway in:
- Prostate cancer (64Cu-SAR-bisPSMA and 64Cu-SAR-Bombesin)
- Neuroendocrine tumours (64Cu-SARTATE)
